Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.

The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.

Argus Aug 26 session

+6.38% close to close Open Argus

Details

News Market Reaction – CRBU

On Aug 26, the first trading day after this news, CRBU closed 6.38% above the previous close.

Data tracked by StockTitan Argus for the Aug 26 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Caribou Biosciences (CRBU) presenting at the Citi 2025 Biopharma Conference?

Caribou Biosciences will present on September 3, 2025 at 2:30 PM EDT.

Who will represent Caribou Biosciences (CRBU) at the Citi 2025 Conference?

Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat.

How can investors access Caribou Biosciences' (CRBU) conference presentation?

The presentation will be available via webcast on Caribou's website Events page and will remain accessible for at least 30 days after the event.

What type of company is Caribou Biosciences (CRBU)?

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company.